抗新生血管药物联合玻璃体切割视网膜复位术治疗严重增殖性糖尿病视网膜病变观察.pdfVIP

• 786 • 中国康复理论与实践 2009 年 8 月第 15 卷第 8 期 Chin J Reha bil Theory Pract , A昭. 2009 , Vo l. 15 , No. 8 ·临床观察· 抗新生血管药物联合玻璃体切割视网膜复位术 治疗严重增殖性糖尿病视网膜病变观察 梁军，王子含 [摘要] 目的探讨抗新生血管药物联合玻璃体切割视网膜复位术治疗严重增殖性糖尿病视网膜病变CPDR) 的临床庇用价 值。方法回顾性分析严重增殖性糖尿病视网膜病变W 期患病者 42 例 50 眼，均于术前1O~14 d 行 Bevacizumab( Avastin) 1. 25 mg/O. 05 ml 玻璃体腔注射，而后联合玻璃体切割视网膜复f技术并眼内填充硅汹或惰性气体。结果 50 眼术后视网膜解剖全部复 位，术中出血较少.所有病例术后验证反成较轻，眼压控制良好，眼内留置硅汹元明显并发症。结论抗新牛血管药物联合波璃体 切割视网膜复位治疗严重增殖11:糖尿病视网膜病变能够明显减少术中出血，减少术后并发症，提高患者术后最佳矫正视力。 [关键词]糖尿病视网膜病变z 药物辅助;Avastin; 玻璃体切除 P翻S Plana Vitrectomy Assisted by Bevecizumab(Avastin) for Proliferative Diabetic Retinopatby LIANG ] un , WANG Zi-han. Bei- jing Intech Eye Hosþital , Beijing 100021 , China Abstract: Objective To evaluate the efficacy of vitrectomy with preoperative intravitreal injection of Bavacizumab CAvastin )for severe proliferative diabetíc retinopathy. Metbods 42 cases (50 eyes ) with severe proliferative diabetis retinopathy treatment by vit- rectomy with preoperative intravitreal injection of Bevacizumab (Avastin )were analyzed retrospectively. 10~14 days before vitrecto my , intravitreal injection of Bevacizumab (Avastin )1. 25mg/0. 05ml was performed on all 50 eyes. 7 eyes with traction retinal de tachment and severe macular edema were tamponed with silicon iol. 43 eyes with regional tractional retinal detachment and retinal hole were tamponed with gas. R四川ts 50 eyes had little hemorrhage during vitrectomy with intravitreal injection of Bevacizumab (Avastin). The retinal are all reattatched after the operation. No more severe inflammatory reaction occured after vitrectomy. The intraocular pressure was under controlled. And there w